OsteoSys
OsteoSys is a publicly listed Seoul-based medical device manufacturer producing DXA bone densitometers, QUS ultrasound scanners, ESWT pain therapy systems, and preclinical DXA cabinets for osteoporosis, sarcopenia, body composition, and musculoskeletal applications, serving hospitals, research institutions, and veterinary labs across 70+ countries with approximately 80% domestic Korean market share.
- Company typePublic
- Founded2000
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What OsteoSys does
Headquartered in Seoul, South Korea, OsteoSys is a publicly listed medical device manufacturer specializing in bone densitometry, body composition analysis, and musculoskeletal therapy equipment. The company develops, manufactures, and sells DXA (Dual-energy X-ray Absorptiometry) systems for clinical osteoporosis and sarcopenia diagnosis, quantitative ultrasound (QUS) devices for portable bone density screening, extracorporeal shock wave therapy (ESWT) systems for musculoskeletal pain, and a dedicated preclinical DXA cabinet (iNSiGHT) for laboratory animal research. OsteoSys commands approximately 80% domestic market share in Korea's bone density DXA segment and exports its products to over 70 countries via a network of 150+ distributors, with documented installations at Harvard Joslin Diabetes Center, the US National Institutes of Health, MD Anderson Cancer Center, Mayo Clinic, Mount Sinai Hospital, the University of Tokyo, and New York University. The company was the first Korean bone densitometer manufacturer to receive EU Medical Device Regulation (MDR 2017/745) certification for its full DXA portfolio, and its Primus whole-body scanner has been recognized by the Korean Ministry of Health and Welfare as a new medical technology for sarcopenia diagnosis since 2019.
OsteoSys's product architecture centers on three technology platforms: (1) DXA-based whole-body, half-body, table, and peripheral scanners (PRIMUS, EXCELLUS, DEXXUM T, DEXXUM T QUANTUM, EXA-3000, EXA-PRESTO) for bone mineral density and body composition measurement; (2) QUS-based portable and stand-alone devices (SONOST 2000, SONOST 3000, BeeTLe) using SOS and BUA measurements at the calcaneus, with the BeeTLe offering wireless NFC/Bluetooth mobile control and a 5-second scan; and (3) the NPT-Sonicure ESWT device employing digital array control with 3D dynamic focusing for pain-free musculoskeletal treatment. The iNSiGHT preclinical platform combines cone beam HFG and flat panel detector technology to deliver 25-second in-vivo body composition scans at 100 micrometer resolution, eliminating the need for animal sacrifice in longitudinal studies. Software integrations include the Medimaps TBS iNsight trabecular bone score module, which adds AI-powered bone microarchitecture analysis to the Primus system.
The company generates revenue through three primary streams: one-time sales of medical device hardware (bone densitometers and ESWT systems) to healthcare providers, hospitals, and research institutions; recurring or licensed software solutions including body composition analysis and TBS iNsight integrations; and ongoing service and maintenance contracts with both domestic (Korea hotline 1551-5099) and international customer support. Distribution combines direct enterprise sales for large Korean and Chinese institutional accounts with an extensive international channel partner network, supplemented by direct public-sector tender wins such as the consecutive Turkish Ministry of Health contracts. Pricing is quote-based and not publicly disclosed, consistent with the enterprise medical device sales model. OsteoSys maintains offices in Seoul (headquarters) and Shanghai (China regional), is led by founder and CEO Young-bok Ahn, and is publicly listed on the Korea Stock Exchange (KOSPI).
OsteoSys firmographics
Firmographics- Name
- OsteoSys
- Legal name
- OSTEOSYS Corp. (주식회사 오스테오시스)
- Website
- https://osteosys.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- OsteoSys is a publicly listed Seoul-based medical device manufacturer producing DXA bone densitometers, QUS ultrasound scanners, ESWT pain therapy systems, and preclinical DXA cabinets for osteoporosis, sarcopenia, body composition, and musculoskeletal applications, serving hospitals, research institutions, and veterinary labs across 70+ countries with approximately 80% domestic Korean market share.
- Ownership category
- akta.pro rank
OsteoSys industry classification
Industry- Product category
- Bone Densitometry and Musculoskeletal Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- X-ray & Fluoroscopy Systems (HLAHABAA)
- akta.pro secondary industry
- Pain Management (Spine & Musculoskeletal) (HLAKALAM)
Keywords
Where OsteoSys is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
OsteoSys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales: Sale of bone mineral density diagnostic equipment (DXA systems, QUS devices) and ESWT treatment devices to healthcare providers, hospitals, and research institutions.
- Software Solutions: Sale of related software solutions including body composition analysis software, BMD reporting systems, and TBS iNsight integration for enhanced bone health assessment.
- Service and Maintenance: Customer service and support including remote support services, domestic service hotline (1551-5099), and overseas service support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise/Institutional Pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
OsteoSys product offering
Product offeringCore offering
OsteoSys manufactures and sells bone mineral density (BMD) diagnostic systems based on Dual Energy X-ray Absorptiometry (DXA) and Quantitative Ultrasound (QUS), body composition analyzers, Extracorporeal Shock Wave Therapy (ESWT) devices for musculoskeletal pain, and preclinical/veterinary DXA imaging cabinets. Its products serve hospitals, clinics, research institutions, universities and government health programs for osteoporosis diagnosis, sarcopenia assessment, body composition analysis and musculoskeletal pain therapy.
Product overview
OsteoSys is a medical device manufacturer specializing in bone health diagnostic equipment and musculoskeletal therapy devices. The product portfolio includes: BMD diagnostic systems using DXA technology (PRIMUS whole-body scanner, EXCELLUS half-body scanner, DEXXUM T series, EXA series) and QUS technology (SONOST series, BeeTLe portable device); NPT-Sonicure for extracorporeal shock wave therapy treating musculoskeletal pain conditions; and iNSiGHT for preclinical/veterinary DXA analysis of lab animals. The company holds approximately 80% domestic Korean market share and exports to over 70 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- SoniCure: Brand name for OsteoSys's Extracorporeal Shock Wave Therapy (ESWT) technology products.
Products and services
- PRIMUS Whole-body DXA scanner for bone mineral density and body composition analysis including lean mass, fat mass and bone mass measurements; recognized as new medical technology since 2019 for simultaneous sarcopenia and osteoporosis diagnosis.
- EXCELLUS Half-body DXA scanner for precise measurement of fat mass, muscle mass and bone mineral density with scientific body composition monitoring.
- DEXXUM T Table DXA system for bone mineral density assessment at the spine and hip; EU MDR certified.
- DEXXUM T QUANTUM Advanced table DXA system with quantum technology for enhanced bone density measurements; EU MDR certified.
- EXA-3000 Peripheral DXA system for bone mineral density measurement at specific skeletal sites such as the forearm or heel; EU MDR certified.
- EXA-PRESTO Peripheral DXA device for clinical bone density assessment in office or point-of-care settings.
- SONOST 3000 Portable stand-alone quantitative ultrasound (QUS) bone densitometer with embedded PC, colorful touch screen, built-in thermal printer, temperature compensation and automatic probe positioning; uses SOS and BUA measurements for calcaneal BMD calculation.
- SONOST-2000 Quantitative ultrasound bone densitometer for calcaneal bone mineral density measurement.
- BeeTLe Portable wireless QUS bone mineral densitometer with NFC and Bluetooth functions, providing a 5-second calcaneal BMD test controlled via a mobile phone application through one-touch measurement.
- NPT-Sonicure (SoniCure) Next-generation extracorporeal shock wave therapy (ESWT) device based on digital array control technology with world-first 3D dynamic focusing; provides software-based depth adjustment without gel pad replacement for pain-free musculoskeletal treatment at the skin surface.
- iNSiGHT Fully shielded preclinical DXA cabinet for in-vivo body composition and BMD analysis in lab animals; uses cone beam HFG and a flat panel detector to complete scans in 25 seconds (10 seconds of X-ray exposure) with 100-micron high-resolution imaging, multiple ROIs and longitudinal study capability without requiring animal sacrifice.
Quantifiable outcome
- 80% domestic market share in Korea's bone density DXA device market
- +3 more outcomes
Companies that use OsteoSys
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles4 records
OsteoSys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
OsteoSys partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Medimaps GroupcoreMedimaps Group, a Swiss/Global med-tech company specializing in image processing software for bone health, partnered with OsteoSys to integrate TBS iNsight (Trabecular Bone Score) technology into OsteoSys' Primus Whole Body DXA scanner. This partnership enhances osteoporosis fracture risk assessment by combining BMD measurement with bone microarchitecture analysis using AI-powered technology. TBS iNsight has CE 2797 mark, FDA 510(k) clearance, and is cleared in 60+ countries. The integration expands access to Medimaps' technology throughout Southeast Asia, Europe, and South America.
Scale indicators6 records
Recent moves9 records
Expansion highlights5 records
OsteoSys competitors and assessment
Company assessmentDirect peers
- Hologic: Hologic is the global market leader in DXA bone densitometry (Discovery/Horizon platforms) alongside women's health imaging. It is OsteoSys's most direct competitor in whole-body DXA sales to hospitals and clinics worldwide.
- DMS Group: DMS Group (France) is a specialist DXA and bone densitometry manufacturer (Stratos, Lexxos) competing head-to-head with OsteoSys's PRIMUS, EXCELLUS and DEXXUM T lines in European and emerging-market tenders.
- Norland (CooperSurgical): Norland at CooperSurgical is a legacy DXA bone densitometer brand (XR-Series) with overlapping research and clinical customers. It is a direct substitute for OsteoSys's table DXA systems in osteoporosis and body composition research labs.
Broad incumbents
- Hitachi: Hitachi supplies diagnostic imaging systems including X-ray modalities used in hospitals globally. As a broad incumbent with overlapping imaging channels, it competes with OsteoSys at the hospital capital-equipment procurement level, especially in Asia.
- GE Healthcare: GE Healthcare sells the Lunar iDXA bone densitometer line as part of a much broader diagnostic imaging portfolio. OsteoSys explicitly positions itself as a top-3 global bone densitometry player 'alongside GE and Hologic,' making GE the anchor incumbent peer.
- Swissray: Swissray manufactures digital radiography (DR) X-ray systems used in hospitals and clinics. Its DR X-ray capability overlaps with the X-ray based technology stack underlying OsteoSys's DXA and combined DR X-ray/DXA veterinary platform.
- Philips: Philips Healthcare is a global diagnostic imaging incumbent whose X-ray and women's-health portfolio overlaps with OsteoSys's DXA positioning at large hospital networks and reference centers.
Emerging players
- BeamMed: BeamMed (Israel) develops quantitative ultrasound (QUS) bone densitometry devices (Sunlight Omnisense). It overlaps directly with OsteoSys's SONOST and BeeTLe QUS product lines in pediatric and point-of-care bone assessment.
Others
- Medimaps Group: Medimaps Group (Switzerland) provides TBS iNsight, a CE-marked and FDA-cleared trabecular bone score software that OsteoSys integrates into PRIMUS. It is a strategic partner and adjacent ecosystem peer rather than a direct device competitor.
Regional players
- Furuno Electric: Furuno (Japan) supplies medical imaging and electronic equipment, including diagnostic modalities in the Japanese market. It is a regional peer for OsteoSys's preclinical DXA and bone densitometry exports to Japan (e.g., University of Tokyo).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
OsteoSys social profiles
Digital presenceOsteoSys compliance and trust
Trust signalCompliance1 record
OsteoSys financial estimates
Financial estimateRevenue estimate
Valuation estimate
OsteoSys leadership team
Management profileNumber of profiles
Profiles1 record
OsteoSys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OsteoSys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OsteoSys
What does OsteoSys do?
OsteoSys manufactures and sells bone mineral density (BMD) diagnostic systems based on Dual Energy X-ray Absorptiometry (DXA) and Quantitative Ultrasound (QUS), body composition analyzers, Extracorporeal Shock Wave Therapy (ESWT) devices for musculoskeletal pain, and preclinical/veterinary DXA imaging cabinets. Its products serve hospitals, clinics, research institutions, universities and government health programs for osteoporosis diagnosis, sarcopenia assessment, body composition analysis and musculoskeletal pain therapy.
Is OsteoSys a public or private company?
OsteoSys is a public company. It is classified as public and is currently operating.
When was OsteoSys founded?
OsteoSys was founded in 2000. It employs 51 to 100 people.
Where is OsteoSys based?
OsteoSys is headquartered in Seoul, South Korea, in the Asia region.
How does OsteoSys make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are software Solutions and service and Maintenance.
Who are OsteoSys's main competitors?
Direct peers on record are Hologic, DMS Group and Norland (CooperSurgical). Broad incumbents are Hitachi, GE Healthcare, Swissray and Philips. BeamMed is listed as an emerging player. Medimaps Group is listed as an others. Furuno Electric is listed as a regional player.
Does OsteoSys have an API?
No public API is recorded for OsteoSys.
What industry is OsteoSys in?
OsteoSys's product category is Bone Densitometry and Musculoskeletal Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAA, X-ray & Fluoroscopy Systems, with a secondary code of HLAKALAM, Pain Management (Spine & Musculoskeletal). Its NAICS code is 334510 and its SIC code is 3845.